Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUVAIF)

• Drug Name: ISONICOTINIC ACID Drug Info
• Synonyms: ISONICOTINIC ACID; 55-22-1; Pyridine-4-carboxylic acid; 4-Pyridinecarboxylic acid; 4-Picolinic acid; 4-Carboxypyridine; p-Pyridinecarboxylic acid; gamma-Picolinic acid; gamma-Pyridinecarboxylic acid; Acide iso-nicotinique; 1,4-Dihydroisonicotinic acid; Acide iso-nicotinique [French]; UNII-Y8SYN761TQ; AI3-19239; .gamma.-Picolinic acid; NSC 1483; Isonicotinic acid, 99%; EINECS 200-228-2; Y8SYN761TQ; CHEBI:6032; TWBYWOBDOCUKOW-UHFFFAOYSA-N; MFCD00006429; g-picolinic acid; Isonicotinic Acids; isonicotinicacid; isonicotonic acid; MN1

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5922
  ChEBI ID: CHEBI:6032
  CAS Number: CAS 55-22-1
  TTD Drug ID: DMUVAIF

Molecule-Related Drug Atlas

Drug(s) Targeting Nicotinic acid receptor (HCAR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vitamin B3	DMQVRZH	Chronic renal failure	GB61.Z	Approved	[3]
ARI-3037MO	DM9LNXS	Cardiovascular disease	BA00-BE2Z	Phase 2	[4]
SCH-900271	DMBJY1Z	Ischemic stroke	8B11.5Z	Phase 2	[5]
GSK-256073	DMMAIY2	Hyperlipidaemia	5C80	Phase 2	[6]
MK-1903	DMVJB09	Arteriosclerosis	BD40	Phase 2	[7]
MK-0354	DMWFTRJ	N. A.	N. A.	Phase 2	[8]
NIA-114	DM3ADQW	Plaque psoriasis	EA90.0	Clinical trial	[9]
INCB19602	DMRHZBD	Type-2 diabetes	5A11	Discontinued in Phase 2	[10]
cinnamic acid	DM340FH	Discovery agent	N.A.	Investigative	[11]
5-Benzyl-1H-pyrazole-3-carboxylic acid	DMJVGUZ	Discovery agent	N.A.	Investigative	[1]

Drug(s) Affected By ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[13]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[14]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[16]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[17]
Bortezomib	DMNO38U	Leukemia		Approved	[18]
Omacetaxine mepesuccinate	DMPU2WX	Adult acute monocytic leukemia		Approved	[14]
Novobiocin	DMRFWGK	Bacterial infection	1A00-1C4Z	Approved	[19]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nicotinic acid receptor (HCAR2)	TTWNV8U	HCAR2_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38)	OTG0TTX7	CD38_HUMAN	Gene/Protein Processing	[2]

References

• [1] Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51.
• [2] Expression of CD38 in human promyelocytic leukemia HL-60 cell line during differentiation by niacin-related compounds. Biosci Biotechnol Biochem. 2003 Aug;67(8):1836-9. doi: 10.1271/bbb.67.1836.
• [3] Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Med Chem Lett. 2011 Nov 24;3(1):63-8.
• [6] GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2013 Nov;15(11):1013-21.
• [7] Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med. 2012 Aug 22;4(148):148ra115.
• [8] GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4472-4.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] DOI: 10.1038/scibx.2010.313
• [11] Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G). J Lipid Res. 2009 May;50(5):908-14.
• [12] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [13] All-trans-retinoic acid accelerates the differentiation of human B lymphocytes maturing into plasma cells. Int Immunopharmacol. 2005 Dec;5(13-14):1830-8. doi: 10.1016/j.intimp.2005.06.002. Epub 2005 Jun 21.
• [14] Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms. J Exp Clin Cancer Res. 2019 Jul 15;38(1):308. doi: 10.1186/s13046-019-1295-8.
• [15] Retinoic acid-induced CD38 expression in HL-60 myeloblastic leukemia cells regulates cell differentiation or viability depending on expression levels. J Cell Biochem. 2006 Apr 15;97(6):1328-38. doi: 10.1002/jcb.20745.
• [16] Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008 Feb 1;111(3):1366-77. doi: 10.1182/blood-2007-04-084814. Epub 2007 Oct 25.
• [17] Arginine methylation provides epigenetic transcription memory for retinoid-induced differentiation in myeloid cells. Mol Cell Biol. 2005 Jul;25(13):5648-63.
• [18] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [19] Novobiocin is a novel inducer of CD38 on cells of the myelomonocytic lineage. Biochim Biophys Acta. 2002 Jan 30;1542(1-3):32-40. doi: 10.1016/s0167-4889(01)00163-x.
• [20] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.